[Cholestatic pruritus--pathophysiology and therapy with special reference to treatment with 5-hydroxytryptamine subtype 3 receptor antagonists].
Our current knowledge about the pathophysiology of pruritus (itch) is summarized. Special concern is given to the hypotheses to explain itch due to cholestatic liver diseases (bile acids, generation of hepatic and intestinal pruritogens, endogenous opioids). Drugs used for the treatment of cholestatic itch are discussed in detail. On the basis of successful treatment of cholestatic itch with 5-hydroxytryptamine (serotonin) subtype-3 receptor antagonists the role of serotonin in nociception is discussed.
Schwörer
H
H
Abteilung Gastroenterologie und Endokrinologie, Universitätsklinik Göttingen.
Ramadori
G
G
D000328:Adult; D002648:Child; D002780:Cholestasis, Intrahepatic / Q000150:complications* / Q000188:drug therapy / Q000503:physiopathology; D005260:Female; D006801:Humans; D007211:Indoles / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D009619:Nociceptors / Q000187:drug effects / Q000503:physiopathology; D017294:Ondansetron / Q000009:adverse effects / Q000627:therapeutic use; D011247:Pregnancy; D011537:Pruritus / Q000188:drug therapy / Q000209:etiology* / Q000503:physiopathology; D011985:Receptors, Serotonin / Q000145:classification / Q000502:physiology*; D012702:Serotonin Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D000077526:Tropisetron
D007211:Indoles; D011985:Receptors, Serotonin; D012702:Serotonin Antagonists; D017294:Ondansetron; D000077526:Tropisetron